newsfilter
← Latest News
GlobeNewswire·

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

  • Gyre Therapeutics (NASDAQ: GYRE) announced that management will participate in the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 9:45 a.m. ET in New York, NY.
  • Company management will also attend the Morgan Stanley Healthcare Conference on Wednesday, September 16, 2026, at 1:05 p.m. ET in New York, NY.
  • Both events will be conducted as fireside chats, with live webcasts available plus replays archived for 30 days on the Investors section of the Gyre website.
  • Gyre Therapeutics is a commercial-stage biopharmaceutical company headquartered in San Diego, CA, focused on small-molecule therapeutics for organ fibrosis & inflammatory diseases.
  • The company's subsidiary Cullgen Inc. is a clinical-stage entity developing targeted protein degrader & DAC therapies for cancer & inflammatory diseases.
  • Gyre Pharmaceuticals, a subsidiary in which Gyre Therapeutics holds a 69.7% equity interest as of June 30, 2026, commercialized ETUARY™ (pirfenidone capsule) for IPF in the PRC starting in 2011.
  • Gyre Pharmaceuticals' NDA for F351 (hydronidone) to treat CHB-induced liver fibrosis was accepted by China's NMPA in May 2026, following its Breakthrough Therapy designation in March 2021.
  • Gyre Pharmaceuticals is also developing treatments for PD, RILI, COPD, PAH, & acute/acute-on-chronic liver failure (ALF/ACLF).